Literature DB >> 24313969

Conservative management, surgery and radiosurgery for treatment of vestibular schwannomas: a model-based approach to cost-effectiveness.

C Gait1, E J Frew, T P C Martin, S Jowett, R Irving.   

Abstract

OBJECTIVE: To undertake a cost-effectiveness analysis comparing conservative management, surgery and radiosurgery for treating small-to-medium (1-20 mm)-sized vestibular schwannomas.
DESIGN: Model-based economic evaluation using individual-level data from a Birmingham-based longitudinal patient database and from published sources. Both a decision tree and state-transition (Markov) model were developed, from an National Health Service (NHS) perspective. Sensitivity analyses were also carried out.
SETTING: Secondary care treatment for patients with small-to-medium-sized vestibular schwannomas. PARTICIPANTS: Three hypothetical cohorts of adult patients receiving conservative management, radiosurgery or surgery treatment, aged 58 years as starting age within model. MAIN OUTCOME MEASURES: Cost-effectiveness based on cost per quality-adjusted life year (QALY).
RESULTS: Conservative management is the preferred strategy for the treatment of small-to-medium-sized vestibular schwannomas. Conservative management is both cheaper (-£ 722 and -£ 2764) and more effective (0.136 and 0.554 quality-adjusted life years) than both radiosurgery and surgery, respectively. A conservative strategy can therefore be considered as highly cost-effective. This result is sensitive to the assumed quality-of-life parameters in the model. Sensitivity analysis suggests that the probability of a conservative strategy being the most cost-effective approach compared with surgery and radiosurgery at a willingness to pay of £ 20 000/quality-adjusted life year gained is 80% and 55%, respectively.
CONCLUSIONS: A conservative approach is the preferred strategy for treatment of small-to-medium vestibular schwannomas. This result is sensitive to quality-of-life values used in the analysis. More research is required to assess the impact of treatment upon patients' health-related quality of life over time.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 24313969     DOI: 10.1111/coa.12205

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  6 in total

1.  Bilaterally Abnormal Head Impulse Tests Indicate a Large Cerebellopontine Angle Tumor.

Authors:  Hyo Jung Kim; Seong Ho Park; Ji Soo Kim; Ja Won Koo; Chae Yong Kim; Young Hoon Kim; Jung Ho Han
Journal:  J Clin Neurol       Date:  2016-01       Impact factor: 3.077

2.  Radiotherapy for vestibular schwannoma: Review of recent literature results.

Authors:  Giuseppina Apicella; Marina Paolini; Letizia Deantonio; Laura Masini; Marco Krengli
Journal:  Rep Pract Oncol Radiother       Date:  2016-02-28

3.  Twelve-year results of LINAC-based radiosurgery for vestibular schwannomas.

Authors:  Paola Anselmo; Michelina Casale; Fabio Arcidiacono; Fabio Trippa; Rossella Rispoli; Lorena Draghini; Sara Terenzi; Alessandro Di Marzo; Ernesto Maranzano
Journal:  Strahlenther Onkol       Date:  2019-08-05       Impact factor: 3.621

4.  Auditory brainstem response prior to MRI compared to standalone MRI in the detection of vestibular schwannoma: A modelling study.

Authors:  Stan R W Wijn; Mayke A Hentschel; Andy J Beynon; Henricus P M Kunst; Maroeska M Rovers
Journal:  Clin Otolaryngol       Date:  2021-11-24       Impact factor: 2.729

5.  In search of the most cost-effective monitoring strategy for vestibular schwannoma: A decision analytical modelling study.

Authors:  Mirre Scholte; Mayke A Hentschel; Gerjon Hannink; Henricus P M Kunst; Stefan C Steens; Maroeska M Rovers; Janneke P C Grutters
Journal:  Clin Otolaryngol       Date:  2019-04-11       Impact factor: 2.597

6.  Hearing Outcome After Linear Accelerator-Based Radiotherapy for Vestibular Schwannomas: A Retrospective Analysis of a Single Center.

Authors:  Dominique Valérie Clarence de Jel; Ernst J Smid; Tristan P C van Doormaal; Hans G X M Thomeer
Journal:  J Int Adv Otol       Date:  2021-09       Impact factor: 1.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.